BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 22591635)

  • 1. SOCS3 in immune regulation of inflammatory bowel disease and inflammatory bowel disease-related cancer.
    Li Y; de Haar C; Peppelenbosch MP; van der Woude CJ
    Cytokine Growth Factor Rev; 2012 Jun; 23(3):127-38. PubMed ID: 22591635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SOCS3 and STAT3, major controllers of the outcome of infection with Mycobacterium tuberculosis.
    Rottenberg ME; Carow B
    Semin Immunol; 2014 Dec; 26(6):518-32. PubMed ID: 25458989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulation of IL6/IL6R-STAT3-SOCS3 signaling pathway in IBD-associated colorectal dysplastic lesions as compared to sporadic colorectal adenomas in non-IBD patients.
    Gui X; Iacucci M; Ghosh S
    Pathol Res Pract; 2020 Nov; 216(11):153211. PubMed ID: 32979687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-10 anti-inflammatory response to Borrelia burgdorferi, the agent of Lyme disease: a possible role for suppressors of cytokine signaling 1 and 3.
    Dennis VA; Jefferson A; Singh SR; Ganapamo F; Philipp MT
    Infect Immun; 2006 Oct; 74(10):5780-9. PubMed ID: 16988256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppressors of cytokine signaling and immunity.
    Kubo M; Hanada T; Yoshimura A
    Nat Immunol; 2003 Dec; 4(12):1169-76. PubMed ID: 14639467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease.
    Andoh A; Shioya M; Nishida A; Bamba S; Tsujikawa T; Kim-Mitsuyama S; Fujiyama Y
    J Immunol; 2009 Jul; 183(1):687-95. PubMed ID: 19535621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis.
    Li Y; de Haar C; Chen M; Deuring J; Gerrits MM; Smits R; Xia B; Kuipers EJ; van der Woude CJ
    Gut; 2010 Feb; 59(2):227-35. PubMed ID: 19926618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells.
    Strengell M; Lehtonen A; Matikainen S; Julkunen I
    J Leukoc Biol; 2006 Jun; 79(6):1279-85. PubMed ID: 16551679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The innate immune system and inflammatory bowel disease.
    Davies JM; Abreu MT
    Scand J Gastroenterol; 2015 Jan; 50(1):24-33. PubMed ID: 25523553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis.
    Wong PK; Egan PJ; Croker BA; O'Donnell K; Sims NA; Drake S; Kiu H; McManus EJ; Alexander WS; Roberts AW; Wicks IP
    J Clin Invest; 2006 Jun; 116(6):1571-81. PubMed ID: 16710471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppressors of cytokine signaling 3 is essential for FcγR-mediated inflammatory response via enhancing CCAAT/enhancer-binding protein δ transcriptional activity in macrophages.
    Yan C; Liu Y; Gao H; Wang X
    Exp Cell Res; 2015 Sep; 337(1):120-7. PubMed ID: 26209606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development.
    Waldner MJ; Neurath MF
    Semin Immunol; 2014 Feb; 26(1):75-9. PubMed ID: 24447345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 11 signaling components signal transducer and activator of transcription 3 (STAT3) and suppressor of cytokine signaling 3 (SOCS3) regulate human endometrial stromal cell differentiation.
    Dimitriadis E; Stoikos C; Tan YL; Salamonsen LA
    Endocrinology; 2006 Aug; 147(8):3809-17. PubMed ID: 16709613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cells of the innate and adaptive immunity and their interactions in inflammatory bowel disease.
    Kmieć Z; Cyman M; Ślebioda TJ
    Adv Med Sci; 2017 Mar; 62(1):1-16. PubMed ID: 28126697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation and colorectal cancer.
    Kraus S; Arber N
    Curr Opin Pharmacol; 2009 Aug; 9(4):405-10. PubMed ID: 19589728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppressor of cytokine signalling-3 at pathological levels does not regulate lipopolysaccharide or interleukin-10 control of tumour necrosis factor-alpha production by human monocytes.
    Prêle CM; Keith-Magee AL; Yerkovich ST; Murcha M; Hart PH
    Immunology; 2006 Sep; 119(1):8-17. PubMed ID: 16925527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3.
    Tamiya T; Kashiwagi I; Takahashi R; Yasukawa H; Yoshimura A
    Arterioscler Thromb Vasc Biol; 2011 May; 31(5):980-5. PubMed ID: 21508344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon.
    Rigby RJ; Simmons JG; Greenhalgh CJ; Alexander WS; Lund PK
    Oncogene; 2007 Jul; 26(33):4833-41. PubMed ID: 17297444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Function of Immune Cells in an Adolescent Patient With a Deficiency in the Interleukin-10 Receptor.
    Veenbergen S; van Leeuwen MA; Driessen GJ; Kersseboom R; de Ruiter LF; Raatgeep RHC; Lindenbergh-Kortleve DJ; Simons-Oosterhuis Y; Biermann K; Halley DJJ; de Ridder L; Escher JC; Samsom JN
    J Pediatr Gastroenterol Nutr; 2017 Jul; 65(1):e5-e15. PubMed ID: 28644354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate immunity in inflammatory bowel disease: state of the art.
    Hisamatsu T; Ogata H; Hibi T
    Curr Opin Gastroenterol; 2008 Jul; 24(4):448-54. PubMed ID: 18622158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.